Bavarian Nordic Seeks Partner After RSV Jab Generates Glowing Phase II Data

Danish Biotech CEO Says Commercializing MVA-BN RSV Is Key Objective Now

Solid Phase II data for Bavarian Nordic’s investigational vaccine MVA-BN RSV showed falls in both symptoms and viral load of respiratory syncytial virus in the challenge trial’s adult participants, boosting prospects for a Phase III trial - and for finding a commercial partner.  

Candidate Vaccine MVA-BN RSV Contains Five Different Antigens of RSV virus • Source: Alamy

Bavarian Nordic A/S’s respiratory syncytial virus vaccine program has been markedly de-risked after the administration of candidate MVA-BN RSV in a Phase II adult challenge trial led to a big reduction in viral load compared with placebo, paving the way for talks with regulators for the design of a Phase III study and with prospective partners to commercialize the product.

The Phase II trial enrolled 61 healthy adult volunteers aged 18 to 50 randomized to receive either a single vaccination...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D